Claims for Patent: 8,440,854

Summary for Patent: 8,440,854

Title:	Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17
Abstract:	This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
Inventor(s):	Eric Anderson, Xin Jiang, Melean Visnick
Assignee:	Reata Pharmaceuticals Holdings LLC
Application Number:	US13/356,455
Patent Claims:	1. A pharmaceutical composition comprising a compound of the formula: wherein: Y is hydroxy or NR1R2, wherein: R1 and R2 are independently: hydrogen or hydroxy; or alkyl(C≦12), alkenyl(C≦12), alkynyl(C≦12), aryl(C≦12), aralkyl(C≦12), heteroaryl(C≦12), heteroaralkyl(C≦12), acyl(C≦12), alkoxy(C≦12), alkenyloxy(C≦12), alkynyl-oxy(C≦12), aryloxy(C≦12), aralkoxy(C≦12), heteroaryl-oxy(C≦12), heteroaralkoxy(C≦12), thioacyl(C≦12), alkylsulfonyl(C≦12), alkenylsulfonyl(C≦12), alkynyl-sulfonyl(C≦12), arylsulfonyl(C≦12), aralkyl-sulfonyl(C≦12), heteroarylsulfonyl(C≦12), or hetero-aralkylsulfonyl(C≦12), or a substituted version of any of these groups; or a pharmaceutically acceptable salt, tautomer, or optical isomer thereof; and a pharmaceutically acceptable carrier. 2. The pharmaceutical composition of claim 1, wherein the compound is further defined as: wherein: R1 and R2 are independently: hydrogen; or alkyl(C≦12), alkenyl(C≦12), alkynyl(C≦12), aryl(C≦12), aralkyl(C≦12), heteroaryl(C≦12), heteroaralkyl(C≦12), acyl(C≦12), alkylsulphonyl, alkenylsulphonyl(C≦12), alkynylsulphonyl(C≦12), arylsulphonyl(C≦12), aralkylsulphonyl(C≦12), heteroarylsulphonyl(C≦12), heteroaralkyl-sulphonyl(C≦12), or a substituted version of any of these groups; or pharmaceutically acceptable salts, tautomers, or optical isomers thereof. 3. The pharmaceutical composition of claim 2, wherein the bond joining carbon 9 and carbon 11 of the compound is a double bond. 4. The pharmaceutical composition of claim 2, wherein the bond joining carbon 9 and carbon 11 of the compound is a single bond. 5. The pharmaceutical composition of claim 2, wherein the compound is further defined as: 6. The pharmaceutical composition of claim 1, wherein the composition is formulated for oral delivery. 7. A pharmaceutical composition comprising a compound of the formula: and a pharmaceutically acceptable carrier.